Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma by Runge, Thomas M. et al.
Epidemiology of Barrett’s Esophagus and Esophageal 
Adenocarcinoma
Thomas M. Runge1, Julian A. Abrams2, and Nicholas J. Shaheen1
1University of North Carolina at Chapel Hill, Center for Esophageal Diseases and Swallowing, 
Division of Gastroenterology and Hepatology, Chapel Hill, NC
2Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY
Abstract
Barrett’s esophagus (BE) is a common condition, and is the precursor to esophageal 
adenocarcinoma, a disease with increasing burden in the western world, especially in Caucasian 
males. The incidence of BE increased dramatically during the late-20th century and incidence 
estimates continue to increase, with a prominent male:female ratio. The prevalence is between 0.5 
– 2.0 percent. A number of anthropomorphic and behavioral risk factors exist for BE including 
obesity and tobacco smoking, but GERD is the strongest risk factor, and the risk is more 
pronounced with long-standing GERD. Esophageal adenocarcinoma (EAC) is the most common 
form of esophageal cancer in the U.S. Risk factors include GERD, tobacco smoking, and obesity, 
while NSAIDs and statins may be protective. A major factor predicting progression from non-
dysplastic BE to EAC is the presence of dysplastic changes seen on esophageal histology, 
although a number of issues limit the utility of dysplasia as a marker for disease. Length of the 
involved BE segment is another risk for progression to high-grade dysplasia and cancer. 
Biomarkers have shown promise, but none are approved for clinical use.
Introduction
Barrett’s esophagus (BE) is a condition in which the typical squamous epithelium of the 
esophageal mucosa is replaced with columnar intestinal epithelium1, 2 BE is a known 
precursor to the development of esophageal adenocarcinoma (EAC), a malignancy with a 
dramatically increasing incidence over the past 40 years. 3–5 The risk of EAC among 
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patients with BE is estimated to be 30–125 fold greater than that of the general population.6 
Endoscopically, the prevalence of BE has been estimated at 1–2% in all patients receiving 
endoscopy for any indication, and anywhere from 5 to 15% in patients with symptoms of 
GERD.7 EAC, though uncommon, has a poor prognosis, and is associated with a 5-year 
survival rate of <20% 8, 9
The incidence of EAC in patients with BE is considerably higher than that in the general 
population, but only a minority of BE patients develop EAC, with annual risk estimated at 
0.1–0.5%.10, 11 Reasons for the meteoric rise in the incidence of EAC are not entirely 
known. However, risk factors for the development of BE and EAC have been identified. 
Similarly, risk factors for the progression of BE to EAC have also been identified, and will 
be discussed here.
I. Epidemiology of Barrett’s Esophagus
Prevalence and Incidence of BE
Barrett’s esophagus primarily affects older adults in the developed world. The true 
prevalence in living adults is difficult to ascertain, because individuals with Barrett’s are 
often asymptomatic and do not seek care. One of the earliest estimates of the prevalence of 
BE was via an autopsy study.12 Cameron and colleagues estimated a prevalence of long 
segment BE of 376 cases per 100,000, or roughly 0.4% of the population, and suggested that 
only a small minority of cases were detected clinically.12 Population-based studies have 
provided estimates of the prevalence of BE in the general public. A Swedish study by 
Ronkainen et al13 estimated the prevalence of BE by performing upper endoscopy on 1000 
randomly selected adults. These investigators found BE in 16 (1.6%) of the individuals, with 
5 subjects (0.5%) in their study demonstrating long-segment disease.13
Tertiary care center endoscopy studies have also attempted to estimate the prevalence of BE. 
Rex et al14 performed upper endoscopy in 961 individuals presenting for routine screening 
colonoscopy. These investigators found an overall prevalence of BE of 6.8%, or 65 of 961 
individuals, of whom 12 (1.2%) had LSBE. In patients who reported heartburn, the 
prevalence was slightly higher at 8.3%, but the majority of patients (54%) who were found 
to have BE reported no reflux symptoms. These estimates may be higher than the prevalence 
in the general population, as this tertiary center population of volunteers may have had more 
GERD than a true random sample of the adult population. Zagari et al analyzed 1033 
patients originally identified as part of a large multicenter cross-sectional study on gallstone 
disease.15 Of these patients, 1.3% (13) had histologically confirmed BE, while 0.2% (2) had 
long-segment BE. These estimates suggest that the prevalence of BE is between 0.5 – 2% of 
unselected individuals. In individuals with reflux symptoms, prevalence estimates are more 
variable (Table 1), ranging from 5–15% 16.
Given that the utilization of endoscopy is dependent on the patient’s socioeconomic status, 
access to care, and other non-medical factors, the incidence of BE has historically been very 
difficult to ascertain. However, the incidence of endoscopically-detected BE appears to have 
increased dramatically over the past 30 years, a finding partially attributable to the 
increasing frequency of endoscopy during the same period.17. Data from the U.K.18 and the 
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Netherlands19 however, suggest that incidence rate of BE have increased even after 
controlling for increasing endoscopy rates. These estimates place the increase in BE 
incidence at near 65% between 1997 and 200219 and 159% between 1993 and 2005. 
Alarmingly, the greatest proportional increase in BE diagnosis was in those under age 60, in 
agreement with other work from Europe.18
Age, Sex, and Ethnic Variations in BE
Males, especially Caucasian males, have a strong predilection for the development of BE, 
with a male:female ratio of 2–3:1 in most studies (see Table 2).1, 20 Age at diagnosis can 
vary widely, as many individuals are asymptomatic and undergo diagnostic endoscopy for 
other reasons.21 BE on average is diagnosed in the 6th – 7th decade of life, but may develop 
far earlier22. In addition to the greater overall prevalence of BE in men, there is evidence 
that males develop the disease earlier than females. From a British endoscopy center, Van 
Blankenstein et al reviewed endoscopy records and histology reports of individuals who 
received upper endoscopy at a single center22. Males on average developed BE about 20 
years earlier than females in that study. The overall ratio of BE cases was 2:1 favoring 
males, but in younger adults, the ratio of men to women approached 4:1. 22 A similar trend 
to early development of BE in men was seen in follow-up studies from Europe.18, 19 
Caucasians in general are disproportionately affected compared to other races. 23 In a large 
cross-sectional study, Ford et al, in a sample from the U.K., found that Caucasians had 
significantly higher prevalence of BE compared to Asians or Afro-Caribbean. In that 
population, LSBE was found in 2.9% of Caucasians, compared to 0.31% of Asians and 0.2% 
of Afro-Caribbeans24.
Studies assessing BE prevalence in Latinos also demonstrate that BE is considerably less 
prevalent in Latinos compared to Caucasians. In a large study by Abrams et al, the 
prevalence of BE was significantly lower among those of Latino background than among 
Caucasians (1.7% vs. 6.1%)25. Other studies have corroborated variations in BE prevalence 
among ethnic groups living in the same country, possibly suggesting an effect of yet-
unrecognized polygenetic factors across different ethnicities.
Multiple environmental factors are strongly associated with BE. These factors, such as 
obesity, GERD, and hiatal hernias are more common in developed countries. However, 
genetic factors are likely also at play. Work from twin studies suggests that symptoms of 
GERD, even when adjusted for obesity and other clinical factors, are more concordant in 
monozygotic twins than dizygotic twins.26
Selected risk factors for BE development
GERD—GERD is a central risk factor for BE development. Numerous case-control studies 
have shown that individuals with GERD are 6–8 times more likely to have BE, and the 
propensity to develop BE increases with more severe symptoms (see Table 1)27–29Longer 
duration of GERD may create an environment conducive to the development of BE 30 
However, the presence of reflux symptoms is neither sensitive nor specific for pathologic 
acid reflux31, 32, and indeed symptom severity does not correlate well with BE risk.33, 34 
Some work has suggested that patients with more significant symptoms may be less likely to 
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have BE,35 perhaps because of impaired acid sensitivity of the columnar metaplasia 
compared to normal squamous epithelium. However, longer duration of GERD symptoms 
predicts increased likelihood of BE.27. A systematic review on the association between 
symptoms and BE found no association between reflux symptoms and SSBE (OR 1.15, 95% 
CI: 0.8 – 1.7) but found increased odds of LSBE in those with reflux symptoms (OR 4.92, 
95% CI: 2.0, 12.0).36 Since screening programs target both SSBE and LSBE, significant 
limitations in using symptom severity remain. When patients with Barrett’s are compared to 
those without, the BE patients have abundant evidence of aberrant acid exposure -longer 
episodes of acid exposure, and lower pH, and also weak peristaltic contractions and 
decreased baseline LES tone.37, 38
While epidemiologic data suggest that gastric acid suppression with PPIs may reduce the 
chance of developing dysplasia and cancer 39, the impact PPI use has on development of BE 
is unknown. Among the many adults who suffer from GERD, only a minority will develop 
BE. The prevalence of BE among those with reflux symptoms is higher than that of the 
general population, but the relationship is not fully explained by GERD. Obesity may be a 
common mediator of both GERD and BE. Central adiposity is known to predispose to hiatal 
hernia development,7 increased GERD symptoms40 and even to directly cause LES 
relaxations41
In summary, reflux is associated with GERD. However, symptoms of reflux cannot reliably 
distinguish those with increased acid reflux from those without. It is likely that a genetic 
mileu predisposing to the development of BE combined with prolonged acid exposure and 
mutagenic events, including oxidative stress, may act synergistically in patients who develop 
EAC.
Obesity—Obesity, measured by BMI and central adiposity, has been studied extensively as 
a risk factor for BE. The incidence of BE and EAC have risen dramatically in the past 40–50 
years in Western societies, concurrent with rapid increases in the rate of obesity. From 1976 
to 1991, the prevalence of obesity at all ages rose from 25% to 33%, and it now approaches 
35% in adults.42 Obesity can be assessed in several ways. High body mass indices and 
especially central adiposity have been shown to have a significant association with BE. A 
2009 meta-analysis that included 11 observational studies showed an increase in the risk of 
BE (OR 1.4) in patients with a BMI > 30 kg/m2 compared to those with BMI < 30 kg/m2. 43 
Patients with BE have been shown to have higher BMIs than either general controls or 
individuals with GERD but not BE.44, 45
Because BMI does not take into account the distribution of body fat, the estimated risk 
increase in the obese may actually be poorly estimated by BMI measurements. In fact, more 
recent work has shown that central adiposity, rather than BMI, may be the true driver of 
increased BE risk. Edelstein et al, in a case control study in 2007, found that the overall risk 
of BE was significantly greater in those with high WHR (OR 2.4); the risk of LSBE in these 
patients was even higher (OR 4.3).44 A pooled analysis by Kubo et al found that waist 
circumference, as a proxy measure for central adiposity, increased risk for BE for males (OR 
2.24) and females (OR 3.75). 46 The impact of obesity on BE risk may vary by race as well. 
In a U.S. case-control study, Kramer et al studied the effect of BMI and waist-to-hip ratio 
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(WHR) on BE prevalence, and found that the relationship between WHR and BE was 
strongest and most significant in Caucasians (OR 2.5), while in African-Americans and 
Latinos the associations were not significant. 23 Because of the strength of the relationship 
between WHR and BE was stronger in Caucasians, it was suggested that other ethnic groups 
could potentially carry as-yet unrecognized genes that protect against BE development.23 It 
is possible that the overwhelming male predominance among EAC cases could be explained 
in part by the fact that overweight males distribute fat preferentially to their trunk, and this 
central adiposity drives the risk increase.47
Alcohol—Alcohol use has been studied extensively as a possible risk factor for 
BE.13, 27, 48–50 multiple studies have shown no association between the two, but results have 
been variable.48, 49, 51 Some work has suggested an inverse correlation between wine intake 
and BE risk.48 The most robust evidence we have on the issue comes out of the BEACON 
consortium, in which the data from 5 studies were pooled to assess risk of alcohol use.50 
Among 1,028 cases and 1,282 controls, alcohol use was stratified by gender and by number 
of drinks per day. There was a borderline significant inverse correlation between BE and any 
degree of alcohol intake (OR 0.77, 0.60–1.00). Drinking 3 to <5 drinks per day was 
associated with a statistically significant reduction in BE risk (OR 0.57, 0.38–0.86), but with 
more or less alcohol consumed no statistically significant results were found (although there 
was a trend toward an inverse relationship). When assessing beverage-specific data, wine 
consumption was associated with an inverse risk of BE (OR 0.71)46, 48
At this point the preponderance of evidence supports no association between alcohol intake 
and BE risk. What was at one time thought to be a minor risk factor for BE now appears to 
confer no additional risk at all. Alcohol might indeed be protective, but in order to fully 
answer this question, more data are needed.
Cigarette Smoking—The majority of studies have found an association between cigarette 
smoking and an increased risk of developing BE.52, 53 A pooled analysis of 5 case-control 
studies found a consistent increase in risk of BE over several pack-year cutpoints, with ORs 
ranging from 1.44 – 1.99 (figure 1).53 However, there was significant heterogeneity between 
studies, and exclusion of a single study yielded pooled ORs with a higher magnitude across 
all exposure groups, ranging from 1.75 to 2.89, with an average OR of 2.09.53 To explore a 
possible synergistic effect between GERD and tobacco use in the genesis of BE, these 
investigators conducted additional modeling to assess the concurrent effects of smoking and 
GERD.53 They found that the OR of Barrett’s increased significantly when both GERD and 
smoking were present, compared to when smokers did not have GERD.
However, not all studies have identified smoking as a risk factor for BE. Thrift et al 51 
studied 258 patients with BE in a case-control study from Houston. These patients were 
compared to 2 control groups: one group was composed of patients receiving elective EGD 
for any indication, and the other was composed of primary care patients undergoing 
screening colonoscopy. These researchers found no association between smoking and BE in 
either group, even when stratified by pack-year exposures, length of time smoking, or 
number of cigarettes/day. In a prospective study design, Steevens et al found ORs of 1.33 in 
former smokers and 0.93 in former smokers compared to controls. 49 In conclusion, smoking 
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appears to increase risk of BE, but there is wide variability in risk estimates. Further study 
may clarify the precise role of tobacco in BE pathogenesis.
Helicobacter pylori—Helicobacter pylori (Hp) infection causes chronic gastritis, PUD, 
and gastric adenocarcinoma. Hp is known to have a strong association with intestinal 
metaplasia in the body and antrum of the stomach.54 Temporal associations have been made 
between the decreasing prevalence of Hp infection in developed countries and the increasing 
prevalence of EAC.55 Corley et al showed that Hp was inversely associated with BE (OR 
0.42) in a case-control study design. 56 While the mechanisms underlying this inverse 
association are not fully understood, they may relate to decreased acid production in the 
setting of Hp infection (especially with associated atrophic gastritis) or via alterations in the 
microbiome.
Different strains of H. pylori may have different abilities to induce risk. The presence of the 
cytotoxin-associated gene (CagA) identifies Hp strains more likely to induce gastritis, more 
extensive gastric inflammation, and gastric cancer.57 Vaezi et al addressed the role of Hp in 
a case control study, and found that patients with BE identified at endoscopy were about 3-
fold less likely to be colonized by CagA positive strains than were controls who did not have 
BE.58 However, contradictory findings were noted in a 2009 meta-analysis by Wang et al.59 
Among included studies using endoscopically normal controls, the prevalence of Hp in 
controls was greater than that in BE, but among those that use healthy blood donors as 
controls, BE patients more frequently had Hp infection. The result was a non-significant 
slight trend toward less Hp infection in patients with BE.59 The authors cited a need for 
further study with well-matched cases and controls to make robust conclusions about an 
association between Hp and BE.
Other Possible Risk Factors
Recently, several other possible risk factors for BE have been studied. Low birth weight 
(LBW) has been posited as a possible risk factor for BE given the apparent association 
between preterm birth and systemic inflammation.60. Forssell et al61 have shown from a 
Swedish birth cohort that prematurity is associated with the risk of developing esophagitis, a 
relationship that is most pronounced among those who are small for gestational age (OR 2.5) 
or who are born at ≤ 32 weeks gestation (OR 6.7)61.Follow–up research by this group has 
suggested that the risk of BE was significantly increased in those with the lowest birth 
weights (OR 8.2)62 The risk of EAC appears to be increased with reduced gestational time, 
but the magnitude of effect is smaller (OR 1.1).63
Other factors associated with a proinflammatory state, such as obstructive sleep apnea 
(OSA) and the metabolic syndrome, appear to increase the risk of BE as well. In a case-
control study, Leggett et al found that OSA was associated with an increased risk of BE (OR 
1.8), after controlling for GERD and obesity.64 Increased levels of adipokines and cytokines 
have also been found in BE patients compared to controls.65 These inflammatory markers 
may be the intermediaries partially responsible for increased BE risk seen in those with 
central obesity, OSA, or GERD.
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II. Epidemiology of Esophageal Adenocarcinoma
Prevalence and incidence of EAC
Esophageal adenocarcinoma was once a rare form of esophageal malignancy. Surgical series 
in the early 20th century showed that esophageal adenocarcinoma made up only 0.8 – 3.7% 
of all esophageal malignancies.66 However, by 1990, esophageal adenocarcinoma overtook 
squamous cell carcinoma of the esophagus, and is now the more common of the two in 
developed nations.67 Esophageal adenocarcinoma continues to increase in incidence (Figure 
2, Figure 3) In 2014, there are expected to be 18,170 new esophageal cancers diagnosed in 
the U.S.68 About 15,000 individuals will die from esophageal cancer in 2014, and more than 
half of these will be from EAC.68, 69
Age, Sex, and Ethnic Variations
Esophageal cancer in general affects males in a 4:1 ratio compared to females.68 With EAC 
specifically, incidence is highest in Caucasian men, with a male-female ratio in Caucasians 
that approaches 8:170–72. The reported incidence of esophageal adenocarcinoma has risen 
dramatically over the past 30–40 years3 By some estimates the incidence has increased from 
300% to 500% over this time2, or by 10% annual increase in males, and between 5 and 7% 
annually in females73 In the U.S. from 1975 – 2006, the incidence of EAC increased 7-fold, 
an increase greater than that of any other major malignancy. 74Among women, rates of EAC 
increased from 0.17 per 100,000 in 1975–1979 to 0.74 per 100,000 in 2000–2004.73 With 
EAC similar increases have been seen in the Latino population of the U.S.73 Fewer analyses 
have been done on African-American males or females often because of significantly lower 
numbers of reported cases of disease, yielding unstable estimates of risk.75 In the last quarter 
of the 20th century, males >65 years of age saw the greatest increase in incidence of EAC, 
about 600%.76 Similar increases have been seen in European and some Asian populations as 
well.75, 77 More recent data suggest that when separated by stage of disease at diagnosis, 
incidence of localized EAC have slowed while distant and regional cases have continued a 
rapid ascent (figure 3).72, 76
Multiple studies assessing SEER data have suggested a ratio of EAC cases in Caucasians to 
African-Americans of approximately 5:1.71 These results parallel data on the prevalence of 
both erosive esophagitis and BE in Caucasians versus African-Americans, in which rates are 
significantly higher in Caucasians.25, 78 The increased incidence in EAC among Caucasians 
is somewhat counterintuitive, in that African-Americans, Caucasians and Asians report a 
similar prevalence of heartburn.71, 78 Similarly, across multiple races, women in general 
often have fewer complications of GERD, whereas men are more likely to have erosive 
disease, BE, or EAC.70
The greatest gender disparity in EAC cases is seen in Caucasians, with an 8:1 ratio. In 
African-Americans, a 3:1 ratio is seen, and in Latinos, there is a 7:1 predominance of males 
compare to females.71 Other work has placed male-to-female ratios for Latinos even higher 
than those of Caucasians in some age groups.70
Recent research suggests that age-related incidence rates show similar patterns in different 
ethnic groups, and that older individuals are disproportionately affected. Nordenstedt et al, 
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in an analysis of SEER data, showed that incidence of EAC peaks in the 70 year and older 
category in Caucasians, African-Americans, and Latinos.70 The reasons for the great gender 
disparity in EAC incidence are not known. A greater proportion of abdominal fat, or 
possibly unknown influences of estrogen or testosterone on disease activity and severity are 
possible explanations.70, 79
In the immediate future, the incidence of EAC is expected to continue its increase. Kong et 
al conducted an analysis of 3 models looking at projections of EAC incidence, progression, 
and mortality. According to recent predictions, the incidence of EAC is expected to rise until 
at least 2030 in males (see Figure 4). At that point, the estimates place the incidence of EAC 
at 8.4 to 10.1 per 100,000 person-years.80
Selected risk factors for EAC
GERD—The association between GERD symptoms and EAC risk has been shown to be 
strong, with risk estimates in those with frequent GERD symptoms ranging from three-fold 
to five-fold higher or more compared to asymptomatic controls.40, 81–83 In a pivotal case-
control study out of Sweden in 1999, Lagergren et al found that compared to individuals 
without GERD symptoms, those with recurrent symptoms had a risk of EAC more than 7 
times higher81 Among those with severe and longstanding symptoms, the risk was increased 
dramatically, by a factor of 43 compared to controls (OR 43.5). This association was also 
seen in several other studies 40, 82with estimates of the risk of EAC ranging from threefold 
to fivefold higher in those with GERD. Odds ratios increased with more severe or more 
frequent symptoms.40, 82. Pooled data from the BEACON consortium, analyzed by Cook et 
al83, found similar effects. Those with longer duration of GERD symptoms had an 
approximately 5-fold increase in risk, and this increased to a six-fold increase with 
symptoms longer than 20 years.83
What can we conclude from this information? The relationship between GERD symptoms 
and risk of EAC is predictable and robust. Data supporting this relationship are more robust 
than those supporting the relationship between GERD and BE, in which an inconsistent 
relationship between symptom severity and risk of disease is seen.21 The association 
between GERD and EAC has been less rigorously studied in minority populations and in 
women, and estimates of risk may differ when these patient populations are considered.
Obesity—Obesity is a risk factor for development of EAC, and some authorities have 
suggested that obesity is the central driver of BE and EAC rates in the developed 
world.30, 84 However, the initial rise in EAC incidence predated the obesity epidemic, and 
thus obesity does not fully explain observed EAC incidence trends.85 The risk of EAC in 
patients in the highest categories of BMI has consistently been shown to be 3- to 7-fold 
higher than those with normal body weight.74, 86, 87 This relationship has been reliably 
demonstrated in other population-based studies as well, and, remarkably, occurs whether or 
not reflux is present. Other studies have suggested a linear risk increase with increasing 
BMI.40, 88 (see Figure 5). A pooled analysis of 10 case-control studies assessed the 
relationship between BMI and EAC. Compared with the referent group (BMI <25), 
increasing BMI was associated with increased risk at cutpoints of 30–34.9(OR 2.39), 35.0 – 
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39.9 (OR 2.79), and >40.0 (OR 4.76).89 Prospective studies have shown similar trends. In a 
prospective cohort study design, Abnet et al compared those with BMI 18.5 – 25 (normal 
body weight) to those with obesity (BMI > 30.0) and found that the risk of EAC was 
increased by more than a factor of two (HR 2.1). The risk of EAC increased further in those 
with BMI > 35 (HR 2.64).90
As in BE, the obesity risk in EAC may lie primarily in patients with truncal obesity. In a 
prospective cohort study, Steffen et al found a RR for EAC of 2.6 when comparing those in 
the highest quartile of waist circumference versus those in the lower quartile.91 This has 
been corroborated in other recent studies.92
Tobacco Use—Smokers are reported to have at least twice the risk of EAC as 
nonsmokers.52, 93 However, evidence of a possible dose-response relationship has been 
somewhat inconsistent.93, 94 In 2000, Lagergren et al, in a case-control study, looked at 
possible dose-dependent effects among nearly 200 patients with EAC and 820 controls. In 
their study, no dose-response trend was seen for either cigarette smokers or pipe smokers, 
despite such a relationship being seen with EGJ adenocarcinomas.94 More recently, in 2010, 
Cook et al pooled data on tobacco use and EAC risk in both EAC and EGJ adenocarcinoma 
from the BEACON consortium 93. In this sample, an association between smoking and 
cancer was observed for both EAC (OR 1.96) and EGJ adenocarcinoma (OR 2.18). Risk for 
EAC by gender differed slightly but were not statistically significantly different – there was 
a trend toward higher risk in males (OR 2.10 vs. 1.74 in females). In this study, a dose-
response relationship was seen. Heavy smokers had the highest risk, with ORs of 2.7 (male) 
and 3.6 (female).93 These data provide compelling evidence that EAC risk increases with 
increasing levels of exposure to tobacco. The investigators did not find any modulating 
effects of GERD or BMI on the effect of smoking and EAC risk.
In summary, smoking for any duration appears to increase risk, and smoking more likely 
leads to more risk. After quitting, risk likely decreases, but this effect is not immediate.93 
Much of these observed associations may be due in part to the effects of smoking on both 
GERD and BE risk. Whether smoking increases the risk of EAC in patients with BE is less 
clear.
Alcohol—Alcohol is strongly associated with squamous cell carcinoma of the esophagus. 
However, as is seen with BE, alcohol has been shown to have little correlation with 
development of EAC. In an analysis comparing 260 controls with 227 EAC cases, Anderson 
et al found no association between any beverage type or amount of alcohol with 
development of EAC.95 In a pooled analysis across 11 studies, Freedman et al found no 
increased risk of EAC who use alcohol, irrespective of duration or intensity of use. 96 The 
summary ORs indicated slightly reduced risk in low and moderate alcohol use groups (ORs 
0.78 & 0.77) but there was no association between alcohol and EAC in very low or high 
alcohol-use groups.96
Helicobacter pylori—Hp causes gastric cancer 97, but interestingly the predominance of 
data suggest that Hp infection is associated with a decreased risk of EAC.98 In a case control 
study, Chow et al observed an inverse correlation between Hp infection and esophageal or 
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gastric cardia adenocarcinoma (OR 0.4, 0.2–0.8).57 Similar inverse relationships have been 
shown in other studies.99, 100 The mechanism by which Hp could reduce risk for EAC is not 
known. It has been suggested that the bacteria could reduce the secretion of acid from the 
stomach, either through direct action on parietal cells or through chronic 
inflammation.100, 101 It is not also not known what effect, if any, eradication of Hp might 
have on EAC risk.
NSAIDs—Some reports have indicated a decreased risk of EAC with NSAID use, both 
with aspirin and other non-aspirin drugs.102, 103 Observational studies have had conflicting 
results.104, 105 A prospective cohort study of 713 patients by Sikkema et al found no 
association between NSAIDs and cancer risk104, while Nguyen et al found a reduced risk of 
EAC (OR 0.64) in a nested case-control study in 2010 105. Systematic reviews, however, 
have showed a decreased risk of EAC in those taking NSAIDs. Corley et al found a 
decreased risk among those using NSAIDs or aspirin (OR 0.57, 95% CI: 0.47–0.71),103 A 
more recent meta-analysis by Abnet et al in 2009 also found an inverse correlation between 
NSAID use and esophageal adenocarcinoma (OR 0.64, 95% CI: 0.52–0.79). In summary, 
EAC risk may be slightly reduced by taking NSAIDs, but the magnitude of risk reduction is 
small. A more clear pattern in individual studies would make this conclusion more robust.
III. Progression of BE to EAC
Earlier estimates had placed the annual rate of progression from BE to EAC at 0.5%2, 106. 
However, more recent large cohort studies have reported lower rates of progression, ranging 
from 0.1–0.3%. 10, 11, 107 Clinical guidelines have recommended periodic endoscopic 
surveillance for the detection of dysplasia and early cancer in patients with BE. However, 
surveillance becomes less cost-effective at lower EAC risks, and therefore understanding 
factors associated with progression are key to guiding management.
Dysplasia in BE
Dysplasia in BE is a histologic diagnosis suggesting that epithelial cells have acquired 
genetic or epigenetic alterations which predispose them to the development of malignancy.1 
Dysplasia, when identified in a patient with BE, predicts a higher risk of EAC, but a number 
of issues have limited its utility. For example, sampling error during surveillance endoscopy 
is an obstacle that has hindered the effectiveness of dysplasia as an accurate marker of 
cancer risk. Because dysplasia is not readily distinguished endoscopically from typical BE, 
an area of dysplastic epithelium can easily be missed.108 Thus, even with extensive 
sampling, by the time histology shows dysplasia, cancer may be present.109 Surgical series 
have shown that cancer was often present at referral for esophagectomy when the referral 
was for endoscopically-diagnosed high-grade dysplasia.11, 108 Because of sampling error, 
guidelines recommend use of the Seattle biopsy protocol, an aggressive biopsy technique 
that seeks to minimize sampling error and improve reliability of cancer and dysplasia 
detection110. Studies have shown that strict adherence to the Seattle protocol improves 
detection of HGD and cancer.45 After implementing the strict guidelines, a hospital system 
in the U.K. improved detection of HGD or cancer by more than fourfold.111 Despite the 
benefits of aggressive biopsy protocol, in practice adherence is suboptimal. In a 2009 study 
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by Abrams et al looking at a national pathology database, these biopsy guidelines were 
followed in just over half (51.2%) of over 2200 BE surveillance cases.112 Furthermore, non-
adherence was associated with a significant reduction in dysplasia detection (summary OR 
0.53).
Another issue is the rate of progression. Rates of EAC development in low-grade dysplasia 
(LGD) were once thought to be as high as 7 – 8% or more per year or higher 109, 113–116 
More recent estimates place the annual risk of progression in BE with LGD closer to 0.5% - 
3%, with some newer estimates even lower117. However, these estimates are remarkably 
heterogeneous. (Table 4) Numerous issues confound the accurate interpretation of the 
presence and severity of dysplasia in BE. Even among experienced pathologists, the extent 
of interobserver agreement when diagnosing LGD can be less than 50%.116, 118 Other work 
has shown difficulty in reproducing the diagnosis of BE119. This is due in part to the fact 
that inflammation can cause cytologic atypia in the bases of crypts that mimics dysplasia. 
“Regression” of LGD, or the failure to detect dysplastic changes on subsequent endoscopies, 
also may occur in half or more of patients with LGD.120, 121 Due to uncertainties regarding 
LGD-associated cancer risk, there remains debate over the optimal management strategy in 
these patients. Incidence of EAC or HGD is estimated at 1.1% - 6% annually but some 
estimates are as high as 13.4% per year10, 11, 107, 122, 123 With HGD, inter-observer 
agreement is better but is still less than 90%.108 Given the high cumulative incidence of 
progression from HGD to EAC, current guidelines recommend endoscopic intervention for 
such patients. 124, 125
Factors that increase risk for dysplasia progression
The strongest predictor of progression to HGD or EAC is baseline low grade dysplasia. 
Sikkema et al followed 713 patients with BE with or without LGD for a mean of 4 years, 
and found that the strongest predictor of incident EAC was the presence of LGD (with OR 
9.6)104. In longitudinal studies, progression rates are significantly higher in those with LGD, 
but estimates of increased risk vary widely (See Table 2). Most studies following both non-
dysplastic barrett’s (NDBE) patients and LGD patients have found increased risk in the 4-
fold to 9-fold range if LGD is present11, 126–132 but estimates have ranged from 2-fold to 27-
fold increases in progression rates10, 11, 107, 108, 113, 114, 121, 122, 126, 127, 129–141
When patients’ slides are reviewed by an expert panel of pathologists, the risk of cancer 
progression increases due to many LGD patients being downstaged to NDBE 137, 140 
Curvers et al 137 found an annual progression rate of 9.4% in those with LGD confirmed by 
expert review, compared to an annual risk of 0.53% who were downstaged to NDBE after 
review. This was corroborated by Duits et al in 2014.140 These investigators found that 
approximately 75% of those deemed to have LGD by community pathologists were 
subsequently downgraded to non-dysplastic reads by expert pathologists. Among the quarter 
of patients who had their LGD reading confirmed, progression rates were extremely high − 
9.1% of these patients progressed to either HGD or EAC on an annual basis.
Duration of BE is also a risk factor for disease progression. Sikkema et al found that the 
cumulative incidence of HGD or EAC was 9.6% over 4 years in those with BE duration >10 
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years. In those with BE duration <10 years, the cumulative incidence was 3.1%. Incidence 
was 13.3% in those with esophagitis compared to 3.0% in those without.104
Among those with HGD, the risk of cancer is substantially higher. Reid et al (Reid 2000) 
reported a cancer risk of 59% over 5 years (or 11.8% annually) in patients with HGD at 
index endoscopy, compared to 1.5% annual cancer risk in LGD patients. A meta-analysis 
published in 2008 yielded a crude incidence rate of 5.6% across 4 studies, with point 
estimates of annual incidence rates ranging from 2.3% per year to 10.3% per year. 142 
Endoscopic therapy is highly effective for the eradication of BE and associated dysplasia, 
and is now considered the preferred management strategy for patients with HGD.124
In summary, LGD represents a marker of increased risk of progression to cancer in patients 
with BE. However, the magnitude of risk increase is unclear, as reported progression rates to 
EAC in LGD have been widely variable. This variability is due in part to the poor 
reproducibility of this diagnosis. Patients with HGD are at very high risk of progression to 
cancer, prompting recommendations for therapeutic intervention when it is found. More 
robust data on progression risk may help better tailor surveillance strategies to each patient 
in the future.
BE Segment Length
Other risk factors have been identified that increase the risk of developing EAC in the 
setting of BE. A number of studies have found that the risk of EAC is greater in longer 
segments of BE compared to shorter segments112, 143, 144 A study by Weston et al found that 
the risk increased by a factor of 6 in longer segments.144 Sikkema et al, in a prospective 
study design, found that for every additional cm of BE, the cumulative risk of HGD or EAC 
increased by 11% over 4 years.104 The relationship between segment length and increased 
risk of EAC is not always linear,145 but the preponderance of evidence suggests that greater 
surface area of columnar-lined mucosa correlates with increased cancer risk.
Extent of Dysplasia
Studies have attempted to determine whether greater extent of dysplasia within a Barrett’s 
segment confers increased risk of neoplastic progression. Interestingly, studies have had 
conflicting results as to whether or not more extensive LGD or HGD increases the risk of 
subsequent EAC.107, 139, 146–148 A study by Srivastava suggested that, when looking at 
crypts showing dysplasia (as a criteria for LGD diagnosis), increased fractions of dysplastic 
crypts correlated with an increased EAC risk.146 Buttar et al also found a 4-fold higher risk 
of cancer progression in those with extensive HGD compared to those with unifocal 
HGD.147 However this result could not be duplicated in a follow-up study.148 Intuitively, it 
would seem that the presence of greater numbers of dysplastic crypts would confer an 
increased risk of future cancer. However, in part due to sampling error limitations of 
endoscopic surveillance, the utility of focal vs. multifocal dysplasia as a risk stratification 
tool is unclear.
Runge et al. Page 12













Molecular/Biologic Markers for Progression from BE to Dysplasia/Cancer
Numerous studies have attempted to assess the utility of molecular biomarkers to predict 
progression and assist with risk stratification. If low risk patients can be accurately 
identified, then little or no follow-up may be warranted. Alternatively, chemopreventive or 
endoscopic interventions could be targeted to high-risk patients. However, to date none of 
the candidate biomarkers has been prospectively validated.
P53 may have the most promise of any of the biomarkers for predicting neoplastic 
progression in patients with Barrett’s. Kastelein et al studied the effect of aberrant p53 
expression in a nested case-control study and found striking results. 149 P53 overexpression 
assessed by immunohistochemistry was associated with significantly increased risk of 
progression to either HGD or EAC (RR 5.6, 95% CI: 3.1, 10.3). Among those with loss of 
p53 expression, the risk of progression was even higher (RR 14.0, 95% CI: 5.3, 37.2). LGD 
alone was far less predictive of progression (RR 2.4, 95% CI: 0.9, 6.0), and the positive 
predictive value of progression was 15% with LGD alone compared to 33% in patients with 
both LGD and aberrant p53 expression.149 P53 has been found to increase the risk of 
progression in other studies as well. In a prospective cohort study, Reid et al found that loss 
of heterozygosity (LOH) of the chromosome harboring p53 was associated with a 7-fold 
increase in progression risk.150151
In a prospective study design, Reid et al analyzed abnormalities in genetic content by flow 
cytometry and found that, among patients with HGD, incidence of esophageal cancer varied 
from 58% over 3 years in patients with baseline cytologic abnormalities, to 7.7% in those 
without baseline cytometric changes.108 In such lower risk patients, a less invasive 
management strategy might be warranted. Bird-Lieberman et al performed a retrospective, 
nested case-control study from a large cohort of patients in Northern Ireland. In that study, 
low-grade dysplasia, abnormal DNA ploidy, and Aspergillus oryzae lectin (AOL) were all 
risk factors for progression. Expert LGD contributed significantly, but AOL (OR 3.7) and 
ploidy (OR 2.8) were also independent predictors of advancement to EAC.152
Another retrospective study found that among 322 patients with BE, aneupoloidy and/or 
tetraploidy, when assessed by flow cytometry, was associated with a RR of 11.7 for 
neoplastic progression to cancer.153
Fluorescence in situ hybridization (FISH) is a method by which a tissue sample can be tested 
for a panel of genetic abnormalities.154 A prospective study by Davelaar et al tested a 
protocol comparing p53 staining by immunohistochemistry and FISH on brush cytology 
specimens.155 They found that p53 abnormalities detected by immunohistochemistry (OR 
17, 95% 3.2, 96) and FISH (OR 7.3, 95% CI: 1.3, 41) were both independent predictors of 
progression. In addition, when both p53 and FISH were used, detection of LGD, HGD, and 
EAC was 100% accurate, both p53 and FISH improved the risk stratification capability of 
p53 alone, and because flow cytometry requires frozen sections of tissue (something rarely 
done in clinical practice),45 the potential for clinical use of FISH may be greater.
Despite the significant advances in biomarker development, significant barriers remain. Of 
all the biomarkers currently identified, the greatest potential for clinical application may lie 
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with assays using p53. p53 can be easily tested, and in multiple studies has been documented 
to improve the reproducibility of the diagnosis of dysplasia and to predict neoplastic 
progression.154 Due to the imperfect nature of dysplasia alone as a predictor of neoplastic 
progressions, work on molecular biomarkers continues at a fervent pace. To date, however, 
no biomarkers are approved for diagnosis or risk stratification, and the most recent 
guidelines from the American Gastoenterological Association recommend against use of 
molecular biomarkers for risk stratification.45 Recent British Society of Gastroenterology 
guidelines propose that p53 immunostaining should be considered, in addition to routine 
clinical diagnosis, for BE diagnosis.125 However, Pathology societies have yet to develop 
guidelines for the interpretation and reporting of p53 staining by IHC in Barrett’s esophagus.
CONCLUSION
There has been a remarkable rise in the incidence of esophageal adenocarcinoma. In 
addition, the spectrum of BE and EAC presents multiple challenges to the medical system. 
Rapidly increasing incidence, high mortality from EAC, and difficulties with risk 
stratification all are issues to be overcome for effective intervention in this disease state. 
Some risk factors for BE and EAC are modifiable, such as tobacco use and obesity. In 
addition to these clinical factors, continued rigorous study of appropriate methods for risk 
stratification continues. Molecular and genetic biomarkers have considerable promise in risk 
prediction models, and may in the future appear as part of a prognostic panel, designed to 
help clinicians focus attention on those most at risk.
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1. Barrett’s esophagus is a precursor to esophageal adenocarcinoma
2. The incidence of esophageal adenocarcinoma has increased dramatically and is 
the most common form of esophageal cancer in the U.S.
3. The strongest risk factor for Barrett’s esophagus is gastroesophageal reflux 
(GERD), however central adiposity and tobacco smoking also increase risk.
4. Risk factors for esophageal adenocarcinoma include GERD, tobacco somking, 
and obesity, while Helicobacter pylori and NSAIDs may be protective.
5. Dysplastic changes seen on biopsy predict progression of Barrett’s to 
esophageal adenocarcinoma, but estimates of the incidence of EAC in dysplastic 
Barrett’s epithelium vary
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Forrest plots summarizing the association between smoking and the risk of BE, using 
population controls. Smoking exposure is grouped by categories. Large unfilled diamonds 
represent the pooled estimates across all studies within that category. The width of the 
diamonds represents the 95% CIs. Black squares indicate the point estimate for each 
individual study. KPNC, Kaiser Permanente Northern California; UNC, University of North 
Carolina. Adapted from Cook et al, “Cigarette Smoking Increases Risk of Barrett’s 
Esophagus: An Analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium.” 
Gastroenterol 142 (2012): 744–753; with permission.
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Incidence and Incidence-based mortality from esophageal adenocarcinoma, 1975 – 2009. 
Produced from SEER 9 data. From Hur et al “Trends in Esophageal Adenocarcinoma 
Incidence and Mortality,” Cancer 119(6): 1149-58; with permission.
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Incidence and incidence-based mortality by stage, for (A) Local, (B) Regional, and (C) 
Distant spread of disease. Produced from SEER 9 data. From Hur et al “Trends in 
Esophageal Adenocarcinoma Incidence and Mortality,” Cancer 119 (6): 1149-58; with 
permission.
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Predicted incidence rates of EAC through 2030 for all males. Figure depicts yearly SEER 
data (black line) overlying simulation models from Massachusetts General Hospital (MGH) 
and the Fred Hutchinson Cancer Research Center (FHCRH), as well as the University of 
Washington and the Microsimulation Screening Analysis model (UW-MISCAN). From 
Kong et al, “Exploring the recent trend in esophageal adenocarcinoma incidence and 
mortality using comparative simulation modeling.” Cancer Epidemiol Biomarkers 23 
(2014): 997-1006; with permission.
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Restricted cubic regression splines depicting the relationship between body mass index and 
adenocarcinomas of the esophagus and esophageal junction.
From Hoyo et al, “Body mass index in relation to oesophageal and oesophagogastric 
junction adenocarcinomas: a pooled analysis from the international BEACON consortium.” 
Int J. Epidemiol 41 (2012): 1706-1718; with permission.
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